AOD-9604 Peptide

One of the most-cited investigations of AOD-9604 is the Phase 2b randomized, double-blind, placebo-controlled study by Heffernan and colleagues, evaluating the lipolytic fragment in obese adult subjects over a 12-week treatment window. The trial enrolled 502 obese participants (BMI 30-40 kg/m²) randomized across multiple oral dose arms (1 mg, 5 mg, 10 mg, 30 mg) versus placebo, with a primary endpoint of change in body weight from baseline.

Study Design

• Subjects: 502 obese adults (BMI 30-40)
• Duration: 12 weeks of daily oral dosing
• Arms: Placebo vs. 1, 5, 10, and 30 mg AOD-9604
• Primary endpoint: Body weight change from baseline
• Secondary endpoints: Lipid profile, glucose tolerance, IGF-1 levels, safety markers

Key Findings

• Subjects receiving 1 mg AOD-9604 exhibited a mean body weight reduction of approximately 2.6 kg at week 12, significantly greater than placebo (p < 0.05).
• Higher doses (10-30 mg) did not produce proportionally greater weight reduction, suggesting a non-linear dose-response curve consistent with receptor-independent lipolytic signaling.
• No significant elevation in IGF-1 was observed at any dose, supporting the hypothesis that AOD-9604 acts independently of the somatotropic axis.
• No clinically meaningful changes in fasting glucose or insulin sensitivity were detected, distinguishing AOD-9604 from full-length hGH which is known to induce insulin resistance.
• Adverse event profile was comparable to placebo across all dose arms in this preclinical/clinical research dataset.

Research Context

This study established the foundational pharmacological profile of AOD-9604 as a fragment that retains the lipolytic and anti-lipogenic properties of the parent hGH C-terminal domain (residues 176-191) without the diabetogenic and growth-promoting effects mediated through the GH receptor. Notably, the absence of IGF-1 elevation in this trial differentiates AOD-9604 from secretagogues such as MK-677 or ipamorelin/CJC-1295 combinations, which work via the GHRH/ghrelin axis. The findings have positioned AOD-9604 as a research tool for studying receptor-independent lipid mobilization and have informed subsequent investigations into its role in adipocyte beta-3 adrenergic signaling and hormone-sensitive lipase activation.

Follow-up research has examined whether the lipolytic fragment displays tissue-selective effects, with particular interest in visceral versus subcutaneous adipose depots. Although the original Phase 2b study did not include detailed body composition imaging, subsequent preclinical work in rodent models has suggested preferential mobilization of visceral fat stores, an area of active ongoing investigation.

The lipolytic activity of AOD-9604 was first characterized in a series of preclinical studies conducted by Ng and colleagues at Monash University, which established the peptide as a functional mimetic of the C-terminal lipolytic domain of human growth hormone (hGH 176-191). These foundational studies provided the mechanistic rationale for subsequent clinical development of the fragment as a metabolic research tool.

In vitro adipocyte studies demonstrated that AOD-9604 stimulates lipolysis in isolated rat epididymal adipocytes in a dose-dependent manner. Heffernan et al. (2001) reported that the peptide increased glycerol release from adipocytes at concentrations comparable to full-length hGH, while showing no effect on glucose oxidation or amino acid incorporation — distinguishing its action from the anabolic effects of intact growth hormone. The lipolytic response was preserved in adipocytes from both lean and obese animal models.

Key preclinical findings included:

• Increased lipolysis: AOD-9604 produced a 2-3 fold increase in glycerol release from adipocytes versus vehicle control in ex vivo assays.
• Reduced lipogenesis: Acetate incorporation into lipid was decreased by approximately 30-40%, suggesting dual action on fat accumulation pathways.
• Body weight reduction: In obese (ob/ob) mice, daily administration over 14-19 days produced significant reductions in body weight gain compared to vehicle-treated controls.
• No diabetogenic effect: Unlike full-length hGH, AOD-9604 did not impair glucose tolerance or elevate fasting insulin in treated animals, even at high doses.
• β3-adrenergic involvement: Lipolytic effects were attenuated in β3-adrenoceptor knockout mice, supporting receptor-mediated signaling.

Mechanistic context: The preclinical data positioned AOD-9604 as a research peptide that selectively recapitulates the metabolic (lipolytic) effects of growth hormone while lacking the somatogenic effects mediated by GH receptor activation at hepatocytes and chondrocytes. This selectivity profile is attributed to the fragment's inability to bind the full GH receptor with sufficient affinity to trigger JAK2/STAT5 signaling, while retaining a binding site relevant to adipocyte β3-adrenergic pathway modulation.

These foundational studies informed the dosing regimens used in subsequent human Phase 1 and Phase 2 trials, where doses of 250-1000 µg were investigated for metabolic effects. The preclinical lipolysis data continue to serve as a reference benchmark for comparative research with other hGH fragments and lipolytic peptides in adipocyte biology.

Beyond its established lipolytic profile, AOD-9604 has been investigated in preclinical models of osteoarthritis and cartilage repair. This research direction emerged from observations that the parent growth hormone molecule exerts trophic effects on chondrocytes and that the C-terminal fragment retained certain regenerative signaling properties even after the somatogenic domain was removed.

Rat osteoarthritis model (Kwon et al., 2015): Investigators evaluated AOD-9604 in a collagenase-induced osteoarthritis model in Sprague-Dawley rats. Animals received intra-articular injections of the peptide alone or in combination with hyaluronic acid over a 4-week observation period. Outcomes included histopathological scoring (OARSI grade), micro-CT analysis of subchondral bone, and biochemical markers of cartilage turnover.

Key observations:

• Reduced cartilage degradation: OARSI histological scores were significantly lower in AOD-9604-treated joints versus saline controls (p < 0.05).
• Synergy with hyaluronic acid: Combined treatment produced greater chondroprotection than either agent alone, with preserved proteoglycan content on Safranin-O staining.
• Subchondral bone preservation: Micro-CT analysis showed reduced subchondral sclerosis in treated joints.
• Anti-inflammatory profile: Reduced expression of MMP-13 and IL-1β in synovial tissue suggested modulation of catabolic pathways.

Mechanistic discussion: The chondroprotective effects observed in these models are thought to involve modulation of inflammatory cytokine signaling and possibly direct effects on chondrocyte metabolism, though the precise receptor interactions remain incompletely characterized. AOD-9604 does not appear to act through the IGF-1 axis in these models, distinguishing it from full-length growth hormone, which exerts cartilage effects largely via hepatic IGF-1 production.

Research significance: These findings expanded the experimental scope of AOD-9604 beyond pure metabolic applications and have prompted continued interest in its use as a comparator peptide in joint and connective tissue research. AOD-9604 has been studied alongside other regenerative peptides such as BPC-157 and TB-500 in cartilage repair contexts, though direct head-to-head comparisons in standardized osteoarthritis models remain limited.

It is important to note that all human clinical data for AOD-9604 to date have focused on metabolic endpoints; joint and cartilage applications remain preclinical. Researchers using AOD-9604 in cartilage models should account for the lack of established pharmacokinetic data for intra-articular administration and the absence of receptor-level characterization in chondrocyte systems.